By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Inhibikase Therapeutics 

3375 Spring Hill Parkway SE
Suite 811
Smyrna  Georgia  30080  U.S.A.
Phone: 917-494-0831 Fax: n/a



Company News
Inhibikase Therapeutics Launches Clinical Study For Survivors Of PML 8/13/2015 6:28:21 AM
Inhibikase Therapeutics Awarded $1.54 Million To Advance Its Proprietary RAMP Chemistry Program To The Clinic 6/29/2015 6:41:28 AM
Inhibikase Therapeutics Elects Richard Fante And Patrick Vink To Its Board Of Directors 5/4/2015 11:14:33 AM
Inhibikase Therapeutics Receives Orphan Drug Designation For Treatment Of Progressive Multifocal Leukoencephalopathy (PML) 5/21/2014 9:37:16 AM
Inhibikase Therapeutics Elects Anthony Zook To The Board Of Directors 11/21/2013 6:59:15 AM
Inhibikase Therapeutics to Present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 5/23/2013 6:45:43 AM
Inhibikase Therapeutics to Present at 5th International Congress on Polyomaviruses and Human Diseases 4/25/2013 7:33:42 AM
Inhibikase Therapeutics Elects Peter Mueller, Ph.D., to Board of Directors 3/9/2012 10:01:19 AM
Bristol-Myers Squibb Company (BMY) Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibikase Therapeutics 2/3/2012 6:40:37 AM
Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients 8/16/2011 11:03:06 AM